{"id":549175,"date":"2021-06-23T15:48:01","date_gmt":"2021-06-23T15:48:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=549175"},"modified":"2021-06-23T15:48:01","modified_gmt":"2021-06-23T15:48:01","slug":"the-high-prevalence-of-type-1-diabetes-as-well-as-participation-of-the-key-players-like-provention-bio-oramed-and-tolerion-and-others-will-influence-the-type-1-diabetes-market-dynamics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/the-high-prevalence-of-type-1-diabetes-as-well-as-participation-of-the-key-players-like-provention-bio-oramed-and-tolerion-and-others-will-influence-the-type-1-diabetes-market-dynamics_549175.html","title":{"rendered":"The High Prevalence of Type 1 Diabetes as well as participation of the Key Players like, Provention Bio, Oramed and Tolerion, and others will influence the Type 1 Diabetes Market Dynamics"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1624440870.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"The High Prevalence of Type 1 Diabetes as well as participation of the Key Players like, Provention Bio, Oramed and Tolerion, and others will influence the Type 1 Diabetes Market Dynamics\" src=\"https:\/\/www.abnewswire.com\/uploads\/1624440870.png\" alt=\"The High Prevalence of Type 1 Diabetes as well as participation of the Key Players like, Provention Bio, Oramed and Tolerion, and others will influence the Type 1 Diabetes Market Dynamics\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Type 1 Diabetes Market <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Owing to the rising prevalence and the projected launch of new therapies such as Teplizumab (Provention Bio), TOL-3021 (Tolerion), Ladarixin (Dompe Pharmaceutical), AG019 (ActoBiotics), ORMD-0801 (Oramed) and others, the Type 1 Diabetes market is predicted to rise during the forecast period, 2021\u20132030.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/947b7241bcbbe13f38c075b0b4b2307e.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The<strong>&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/type-1-diabetes-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Type 1 Diabetes market report<\/a>&nbsp;<\/strong>from DelveInsight provides an in-depth understanding of Type 1 Diabetes, historical and forecasted epidemiology, and Type 1 Diabetes market trends in the 7MM. The report also examines current Type 1 Diabetes treatment practices\/algorithms, market drivers, market constraints, and unmet medical needs in order to identify and evaluate the market&#8217;s underlying potential.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the Important findings from the Type 1 Diabetes Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to the National Diabetes Statistics Report (2020), the United States has <strong>34.2 million<\/strong> people with diabetes in 2018, accounting for <strong>10.5 percent<\/strong> of the total population.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In 2018, <strong>210,000 <\/strong>children and adolescents under the age of 20 in the United States&nbsp; were found to be diabetic, of which <strong>187,000<\/strong> peoplehad Type 1 Diabetes diagnosis (National Diabetes Statistics Report, 2020).<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rosenbauer et al. (2019) study showed that males had a greater Type 1 Diabetes prevalence over females in a group of patients over the age of 18.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Type 1 Diabetes pipelines therapies include <strong>Teplizumab (Provention Bio), TOL-3021 (Tolerion), Ladarixin (Dompe Pharmaceutical), AG019 (ActoBiotics), ORMD-0801 (Oramed)&nbsp;<\/strong>and several others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Several pharmaceutical companies such as <strong>Provention Bio, Tolerion, Dompe Pharmaceutical, ActoBiotics, Oramed<\/strong> and others are developing novel products for Type 1 Diabetes treatment.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">For further information, request sample @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\"><strong>Type 1 Diabetes Management<\/strong>&nbsp;<\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Type 1 Diabetes market report covers current treatment practices, new pharmaceuticals, individual therapy market share, and present and predicted Type 1 Diabetes market size from 2018 to 2030, segmented by seven major markets.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Type 1 Diabetes: Overview<\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Diabetes is a long-term metabolic disease marked by high or low blood glucose (or blood sugar) levels, which can cause considerable damage to the heart, blood vessels, eyes, kidneys, and nerves. Type 1 Diabetes (TD-1), Type 1 Diabetes (TD2), and Gestational Diabetes are the three kinds of diabetes classified clinically.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Type 1 Diabetes is an autoimmune condition that affects the body&#8217;s immune system. It is the most prevalent type of diabetes in children, but it can strike anyone at any age. The common Type 1 Diabetes symptoms include excessive thirst, impaired vision, dry mouth, upset stomach and vomiting, bedwetting, frequent urination, unexplained weight loss, exhaustion, difficulty breathing, lack of energy, and persistent hunger.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Type 1 Diabetes Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Type 1 Diabetes Total Prevalent Cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Type 1 Diabetes Total Diagnosed Prevalent Cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Type 1 Diabetes Total Gender-Specific Prevalent Diagnosed Cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Type 1 Diabetes Total Age-Specific Prevalent Diagnosed Cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Type 1 Diabetes Treated Cases&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Type 1 Diabetes Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">People with Type 1 Diabetes must follow a different plan. A treatment plan, also known as a diabetes management plan, assists people in managing their diabetes while remaining healthy and active. Everyone&#8217;s plan is different, and it is based on a person&#8217;s health needs as well as the recommendations of the diabetes health care team. The treatment&#8217;s goal is to keep your blood sugar levels as close to normal as possible in order to delay or prevent complications.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Forxiga (dapagliflozin) and sotagliflozin (sold as Zynquista)<\/strong> are EMA approved Type 1 Diabetes drugs used for treating the patients with Type 1 Diabetes.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Type 1 Diabetes Market<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Owing to the rising prevalence and the projected launch of new therapies such as <strong>Teplizumab (Provention Bio), TOL-3021 (Tolerion), Ladarixin (Dompe Pharmaceutical), AG019 (ActoBiotics), ORMD-0801 (Oramed)<\/strong> and others, the Type 1 Diabetes market is predicted to rise during the forecast period, 2021&ndash;2030.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get an overview about diabetes @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/type-1-diabetes-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Type 1 Diabetes Market Size<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Type 1 Diabetes Pipeline Therapies and Key Players<\/strong>&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Teplizumab: Provention Bio<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">TOL-3021: Tolerion<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ladarixin: Dompe Pharmaceutical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AG019: ActoBiotics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ORMD-0801: Oramed<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Type 1 Diabetes Market Drivers<\/strong>&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rise in Insulin consumption as the number of diabetic patients increases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Increase in R&amp;D<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Uptake of novel ultra-rapid-acting and ultra-long-acting insulin analogs<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Type 1 Diabetes Market Barriers<\/strong>&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Entry of Biosimilars<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">High treatment and diagnosis Cost<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Inadequate reimbursement policies<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope for the Report<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Coverage:<\/strong> 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Study Period:<\/strong> 2018-30<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Type 1 Diabetes Key Companies:<\/strong> Provention Bio, Tolerion, Dompe Pharmaceutical, ActoBiotics, Oramed, among others.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Type 1 Diabetes Key Pipeline Therapies:<\/strong> Teplizumab (Provention Bio), TOL-3021 (Tolerion), Ladarixin (Dompe Pharmaceutical), AG019 (ActoBiotics), ORMD-0801 (Oramed), and others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Type 1 Diabetes Segmentation:<\/strong> By Geography, By Type 1 Diabetes drugs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis:<\/strong> Comparative and conjoint analysis of Type 1 Diabetes emerging therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Tools Used:<\/strong> SWOT Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Case Studies<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>KOL&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analyst&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong>&nbsp;<\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"77\" \/>\n<col width=\"547\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\">1.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">2.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Executive Summary of Type 1 Diabetes<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">3.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">SWOT Analysis of Type 1 Diabetes<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">4.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Type 1 Diabetes: Patient Share (%) Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">5.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Type 1 Diabetes: Market Overview (%) at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">6.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Type 1 Diabetes Disease Background and Overview&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">7.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Type 1 Diabetes Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">8.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Country-Specific Patient Population of Type 1 Diabetes<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">9.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Type 1 Diabetes Current Treatment and Medical Practices<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">10<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Type 1 Diabetes Patient Journey<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">.11.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Type 1 Diabetes Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">12.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Type 1 Diabetes Key Endpoint of Clinical Trials<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">13.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Type 1 Diabetes Marketed Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">14.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Type 1 Diabetes Emerging Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">15.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Conjoint Analysis of Type 1 Diabetes Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">16.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Type 1 Diabetes: Market Size of 7MM<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">17.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Type 1 Diabetes Country-Wise Market Analysis (2018 &ndash;2030)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">18.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Type 1 Diabetes Market Access and Reimbursement&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">19.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Type 1 Diabetes Market drivers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">20.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Type 1 Diabetes Market barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">21.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">22.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">23.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">24.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">For rich insights into Healthcare and Pharmaceutical News, visit <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dementia-with-diabetes-market-forecast?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Dementia with Diabetes Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get comprehensive historical and forecast analysis of Dementia with Diabetes Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as <strong>vTv Therapeutics, Novo Nordisk,<\/strong> among others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=the-high-prevalence-of-type-1-diabetes-as-well-as-participation-of-the-key-players-like-provention-bio-oramed-and-tolerion-and-others-will-influence-the-type-1-diabetes-market-dynamics\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=the-high-prevalence-of-type-1-diabetes-as-well-as-participation-of-the-key-players-like-provention-bio-oramed-and-tolerion-and-others-will-influence-the-type-1-diabetes-market-dynamics\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Type 1 Diabetes Market Owing to the rising prevalence and the projected launch of new therapies such as Teplizumab (Provention Bio), TOL-3021 (Tolerion), Ladarixin (Dompe Pharmaceutical), AG019 (ActoBiotics), ORMD-0801 (Oramed) and others, the Type 1 Diabetes market is predicted to &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/the-high-prevalence-of-type-1-diabetes-as-well-as-participation-of-the-key-players-like-provention-bio-oramed-and-tolerion-and-others-will-influence-the-type-1-diabetes-market-dynamics_549175.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,406,420,443,416],"tags":[],"class_list":["post-549175","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Pharmaceuticals-Biotech","category-Science","category-Website-Blog","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/549175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=549175"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/549175\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=549175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=549175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=549175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}